INLYTA
Traitement de patients atteints d’un carcinome rénal avancé (RCC) après échec d’un traitement systémique préalable.
Additional information from the official database
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
5.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
160.0 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
0.437 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
5.6 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | FNIDK |
|
(N/A)
|
- | Substance | FTODK |
|
(N/A)
|
- | Substance | HNIDK |
4622 Egerkingen